Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection
Abstract The COVID-19 pandemic has caused a severe global health and economic crisis, with significant consequences for human mortality and morbidity. Therefore, there is an urgent need for more studies on the immune response to SARS-CoV-2 infection, both to enhance its effectiveness and prevent its...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-43263-y |
| _version_ | 1827770580844150784 |
|---|---|
| author | Camila A Corsini Priscilla S Filgueiras Nathalie BF Almeida Daniel AP de Miranda Sarah VC Gomes Adelina Junia Lourenço Cecilia MF Bicalho Jessica V de Assis Raquel NH Amorim Raphael A Silva Raquel VR Vilela Tulio M Lima Daniel PB de Abreu Renata GF Alvim Leda R Castilho Olindo A Martins-Filho Dayane A Otta Rafaella FQ Grenfell |
| author_facet | Camila A Corsini Priscilla S Filgueiras Nathalie BF Almeida Daniel AP de Miranda Sarah VC Gomes Adelina Junia Lourenço Cecilia MF Bicalho Jessica V de Assis Raquel NH Amorim Raphael A Silva Raquel VR Vilela Tulio M Lima Daniel PB de Abreu Renata GF Alvim Leda R Castilho Olindo A Martins-Filho Dayane A Otta Rafaella FQ Grenfell |
| author_sort | Camila A Corsini |
| collection | DOAJ |
| description | Abstract The COVID-19 pandemic has caused a severe global health and economic crisis, with significant consequences for human mortality and morbidity. Therefore, there is an urgent need for more studies on the immune response to SARS-CoV-2 infection, both to enhance its effectiveness and prevent its deleterious effects. This study presents the chronology of antibodies during six months after infection in hospitalized patients and the kinetics of serum soluble mediators of the cellular response triggered by SARS-CoV-2. Samples and clinical data from 330 patients hospitalized at the Hospital da Baleia in Belo Horizonte, Brazil, who were suspected of having COVID-19, were collected at the time of hospitalization and during 6 months after infection. The immune response was analyzed by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. There was a significant difference in IgM specific antibody titers from the 7th to 60th days after infection between COVID-19 negative and positive patients. Soon after 60 days after infection, antibody levels started to reduce, becoming similar to the antibody levels of the COVID-19 negative patients. IgG specific antibodies started to be detectable after 9 days of infection and antibody levels were comparatively higher in positive patients as soon as after 7 days. Furthermore, IgG levels remained higher in these patients during the complete period of 180 days after infection. The study observed similar antibody profiles between different patient groups. The soluble systemic biomarkers evaluated showed a decrease during the six months after hospitalization, except for CCL11, CXCL8, CCL3, CCL4, CCL5, IL-6, IFN-g, IL-17, IL-5, FGF-basic, PDGF, VEGF, G-CSF, and GM-CSF. The results indicate that IgM antibodies are more prominent in the early stages of infection, while IgG antibodies persist for a longer period. Additionally, the study identified that patients with COVID-19 have elevated levels of biomarkers after symptom onset, which decrease over time. |
| first_indexed | 2024-03-11T12:41:36Z |
| format | Article |
| id | doaj.art-485acd06585e4046b792216b035aa2a4 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-11T12:41:36Z |
| publishDate | 2023-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-485acd06585e4046b792216b035aa2a42023-11-05T12:15:47ZengNature PortfolioScientific Reports2045-23222023-10-0113111010.1038/s41598-023-43263-yAntibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infectionCamila A Corsini0Priscilla S Filgueiras1Nathalie BF Almeida2Daniel AP de Miranda3Sarah VC Gomes4Adelina Junia Lourenço5Cecilia MF Bicalho6Jessica V de Assis7Raquel NH Amorim8Raphael A Silva9Raquel VR Vilela10Tulio M Lima11Daniel PB de Abreu12Renata GF Alvim13Leda R Castilho14Olindo A Martins-Filho15Dayane A Otta16Rafaella FQ Grenfell17Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Hospital da Baleia, Benjamin Guimarães FoundationDiagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Hospital da Baleia, Benjamin Guimarães FoundationHospital da Baleia, Benjamin Guimarães FoundationCell Culture Engineering Laboratory, COPPE, Universidade Federal do Rio de JaneiroCell Culture Engineering Laboratory, COPPE, Universidade Federal do Rio de JaneiroCell Culture Engineering Laboratory, COPPE, Universidade Federal do Rio de JaneiroCell Culture Engineering Laboratory, COPPE, Universidade Federal do Rio de JaneiroGrupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (FIOCRUZ)Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (FIOCRUZ)Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (FIOCRUZ)Abstract The COVID-19 pandemic has caused a severe global health and economic crisis, with significant consequences for human mortality and morbidity. Therefore, there is an urgent need for more studies on the immune response to SARS-CoV-2 infection, both to enhance its effectiveness and prevent its deleterious effects. This study presents the chronology of antibodies during six months after infection in hospitalized patients and the kinetics of serum soluble mediators of the cellular response triggered by SARS-CoV-2. Samples and clinical data from 330 patients hospitalized at the Hospital da Baleia in Belo Horizonte, Brazil, who were suspected of having COVID-19, were collected at the time of hospitalization and during 6 months after infection. The immune response was analyzed by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. There was a significant difference in IgM specific antibody titers from the 7th to 60th days after infection between COVID-19 negative and positive patients. Soon after 60 days after infection, antibody levels started to reduce, becoming similar to the antibody levels of the COVID-19 negative patients. IgG specific antibodies started to be detectable after 9 days of infection and antibody levels were comparatively higher in positive patients as soon as after 7 days. Furthermore, IgG levels remained higher in these patients during the complete period of 180 days after infection. The study observed similar antibody profiles between different patient groups. The soluble systemic biomarkers evaluated showed a decrease during the six months after hospitalization, except for CCL11, CXCL8, CCL3, CCL4, CCL5, IL-6, IFN-g, IL-17, IL-5, FGF-basic, PDGF, VEGF, G-CSF, and GM-CSF. The results indicate that IgM antibodies are more prominent in the early stages of infection, while IgG antibodies persist for a longer period. Additionally, the study identified that patients with COVID-19 have elevated levels of biomarkers after symptom onset, which decrease over time.https://doi.org/10.1038/s41598-023-43263-y |
| spellingShingle | Camila A Corsini Priscilla S Filgueiras Nathalie BF Almeida Daniel AP de Miranda Sarah VC Gomes Adelina Junia Lourenço Cecilia MF Bicalho Jessica V de Assis Raquel NH Amorim Raphael A Silva Raquel VR Vilela Tulio M Lima Daniel PB de Abreu Renata GF Alvim Leda R Castilho Olindo A Martins-Filho Dayane A Otta Rafaella FQ Grenfell Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection Scientific Reports |
| title | Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection |
| title_full | Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection |
| title_fullStr | Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection |
| title_full_unstemmed | Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection |
| title_short | Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection |
| title_sort | antibody response and soluble mediator profile in the first six months following acute sars cov 2 infection |
| url | https://doi.org/10.1038/s41598-023-43263-y |
| work_keys_str_mv | AT camilaacorsini antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT priscillasfilgueiras antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT nathaliebfalmeida antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT danielapdemiranda antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT sarahvcgomes antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT adelinajunialourenco antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT ceciliamfbicalho antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT jessicavdeassis antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT raquelnhamorim antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT raphaelasilva antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT raquelvrvilela antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT tuliomlima antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT danielpbdeabreu antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT renatagfalvim antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT ledarcastilho antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT olindoamartinsfilho antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT dayaneaotta antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection AT rafaellafqgrenfell antibodyresponseandsolublemediatorprofileinthefirstsixmonthsfollowingacutesarscov2infection |